ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Sinopharm and Bavarian Nordic side by side

Their registered studies and the programs behind them, as ClinicalTrials.gov shows them and the companies' own pipelines name them. Counts, not rankings: the companies differ in size, so each number is shown beside its share of that company's own programs.

At a glance

Studies each sponsor leads, with the companies grouped under it. Every number opens the studies it counts.

SinopharmBavarian Nordic
studies on the registry9558
open to participants now182
phase 3 studies under way73
reach primary completion within a year52
programswith a study of their own in two years124

Pipeline by phase

Each program once, at the furthest phase its own studies reached. The bar is the share of that company's programs, so a small company and a large one read on the same scale.

Furthest phaseSinopharmBavarian Nordic
Phase 150%

Bavarian Nordic: 1 of its 4 programs at phase 1

  1. MVA-BN-EBVphase 1
25%
Phase 250%

Bavarian Nordic: 1 of its 4 programs at phase 2

  1. MVA-BN-WEVphase 2
25%
Phase 300%

Bavarian Nordic: 1 of its 4 programs at phase 3

  1. CHIKV VLP vaccinephase 3
25%
Approved, new studies00%

Bavarian Nordic: 1 of its 4 programs at approved, new studies

  1. MVA-BN smallpox vaccineapproved, new study
25%

Readouts ahead

Programs whose next study reaches primary completion in each month, by the sponsor's own estimate. A ring marks a month with a phase 3 readout.

Nov ’26DecJan ’27FebMarAprMayJunJulAugSepOct
Sinopharm2 readouts · 0 phase 3···

Sinopharm, Feb ’27: 1 program whose next study reaches primary completion

  1. MVA-SIBP low dosephase 2 · Feb 28 · NCT07253675

Sinopharm, Mar ’27: 1 program whose next study reaches primary completion

  1. SIBP-A16 injectionphase 2 · Mar 31 · NCT07363837
·······
Bavarian Nordic2 readouts · 0 phase 3

Bavarian Nordic, Nov ’26: 1 program whose next study reaches primary completion

  1. MVA-BN smallpox vaccineapproved, new study · Nov 30 · NCT07199569
··

Bavarian Nordic, Feb ’27: 1 program whose next study reaches primary completion

  1. MVA-BN-WEVphase 2 · Feb 0 · NCT06899802
········
size: programs that monthincludes phase 3Dates are estimates the sponsors file and often move.

Changed in the last 90 days

Since Aug 23, 2026: programs whose first study was registered, programs that reached a new phase, studies stopped, and primary completions moved later (a month or more in phase 3, three otherwise). Stops and dates are read from the registry’s changes, kept since Sep 25, 2026.

Sinopharm

New programs 0

None

Reached a new phase 0

None

Study stopped 0

None

Primary completion later 0

None

Bavarian Nordic

New programs 1

  • MVA-BN-EBVphase 1 · first study · Oct 15 · Epstein-Barr Virus Infections

Reached a new phase 0

None

Study stopped 0

None

Primary completion later 0

None

Where they overlap

Conditions where at least two of them have programs: 2 in all. A program counts in each condition its studies name most.

ConditionSinopharmBavarian Nordic
Mpox, Monkeypoxboth · compare here

Bavarian Nordic in Mpox, Monkeypox: 1 program

  1. MVA-BN smallpox vaccineapproved, new study

Their studies: Bavarian Nordic’s studies of Mpox, Monkeypox in search

Smallpoxboth · compare here

Sinopharm in Smallpox: 1 program

  1. BSY001phase 1

Their studies: Sinopharm’s studies of Smallpox in search

Bavarian Nordic in Smallpox: 1 program

  1. MVA-BN smallpox vaccineapproved, new study

Their studies: Bavarian Nordic’s studies of Smallpox in search

Same targetBetaPro · free during the beta

Programs that act on the same gene, from the company’s own words, a judged reading of NCIt, ChEMBL or the studies, or a rule. A reading by rule is marked rule.

No gene two of them both target, among the programs whose target is known.

A target, or a pathogen for a vaccine, known for: Sinopharm 3 of 12 · Bavarian Nordic 2 of 4 programs. Most early programs are named only by a code and their companies do not say what they act on, so this list is short and grows as targets are read.

What this can't show

  • Only what ClinicalTrials.gov holds: programs run only in other registries are missing.
  • Grouping is ours: subsidiaries and acquisitions counted under the parent, each dated and sourced on the sponsor page.
  • Readout dates are the sponsors’ estimates, not results.
  • A program is a drug as the registry names it: a code its company has not tied to a name counts on its own until it is read, and a study run under a partner’s name counts for the partner.
  • “Same target” covers only the programs whose target is known, from the company’s words, a judged reading or a rule; most early programs say nothing of it.